{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+I+Kidney+Wilms+Tumor&page=2",
    "query": {
      "condition": "Stage I Kidney Wilms Tumor",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+I+Kidney+Wilms+Tumor&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:25:44.576Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00369564",
      "title": "Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Neurotoxicity",
        "Peripheral Neuropathy",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "glutamic acid",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "3 Years to 20 Years"
      },
      "enrollment_count": 250,
      "start_date": "2007-05",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2021-08-11",
      "last_synced_at": "2026-05-22T09:25:44.576Z",
      "location_count": 6,
      "location_summary": "Fort Myers, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 3 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00369564"
    },
    {
      "nct_id": "NCT02536183",
      "title": "A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pediatric Cancer",
        "Solid Tumors",
        "Rhabdomyosarcoma",
        "Ewing Sarcoma",
        "Soft Tissue Sarcomas",
        "Osteosarcoma",
        "Neuroblastoma",
        "Wilms Tumor",
        "Hepatic Tumor",
        "Germ Cell Tumors"
      ],
      "interventions": [
        {
          "name": "Magnetic resonance high intensity focused ultrasound",
          "type": "DEVICE"
        },
        {
          "name": "Lyso-thermosensitive liposomal doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "AeRang Kim",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 2,
      "start_date": "2016-10",
      "completion_date": "2022-10",
      "has_results": false,
      "last_update_posted_date": "2023-08-29",
      "last_synced_at": "2026-05-22T09:25:44.576Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02536183"
    },
    {
      "nct_id": "NCT00020150",
      "title": "Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Childhood Germ Cell Tumor",
        "Extragonadal Germ Cell Tumor",
        "Kidney Cancer",
        "Liver Cancer",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Sarcoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "O6-benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": null,
      "start_date": "2000-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-04-29",
      "last_synced_at": "2026-05-22T09:25:44.576Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00020150"
    },
    {
      "nct_id": "NCT04483778",
      "title": "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pediatric Solid Tumor",
        "Germ Cell Tumor",
        "Retinoblastoma",
        "Hepatoblastoma",
        "Wilms Tumor",
        "Rhabdoid Tumor",
        "Carcinoma",
        "Osteosarcoma",
        "Ewing Sarcoma",
        "Rhabdomyosarcoma",
        "Synovial Sarcoma",
        "Clear Cell Sarcoma",
        "Malignant Peripheral Nerve Sheath Tumors",
        "Desmoplastic Small Round Cell Tumor",
        "Soft Tissue Sarcoma",
        "Neuroblastoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "second generation 4-1BBζ B7H3-EGFRt-DHFR",
          "type": "BIOLOGICAL"
        },
        {
          "name": "second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "0 Years to 26 Years"
      },
      "enrollment_count": 68,
      "start_date": "2020-07-13",
      "completion_date": "2040-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-05-22T09:25:44.576Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04483778"
    },
    {
      "nct_id": "NCT00831844",
      "title": "Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Rhabdomyosarcoma",
        "Adult Synovial Sarcoma",
        "Childhood Hepatoblastoma",
        "Childhood Synovial Sarcoma",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Recurrent Adrenocortical Carcinoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Childhood Liver Cancer",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive",
        "Neuroectodermal Tumor",
        "Recurrent Neuroblastoma",
        "Recurrent Osteosarcoma",
        "Recurrent Retinoblastoma",
        "Recurrent Wilms Tumor and Other Childhood Kidney Tumors"
      ],
      "interventions": [
        {
          "name": "cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "7 Months to 30 Years"
      },
      "enrollment_count": 116,
      "start_date": "2009-01",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2015-03-30",
      "last_synced_at": "2026-05-22T09:25:44.576Z",
      "location_count": 93,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00831844"
    },
    {
      "nct_id": "NCT00101270",
      "title": "Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Burkitt Lymphoma",
        "Childhood Central Nervous System Germ Cell Tumor",
        "Childhood Diffuse Large Cell Lymphoma",
        "Childhood Grade III Lymphomatoid Granulomatosis",
        "Childhood Immunoblastic Large Cell Lymphoma",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Grade III Lymphomatoid Granulomatosis",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Liver Cancer",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Malignant Germ Cell Tumor",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Visual Pathway Glioma",
        "Recurrent Colon Cancer",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Melanoma",
        "Recurrent Nasopharyngeal Cancer",
        "Recurrent Neuroblastoma",
        "Recurrent Osteosarcoma",
        "Recurrent Wilms Tumor and Other Childhood Kidney Tumors",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 24,
      "start_date": "2005-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-05",
      "last_synced_at": "2026-05-22T09:25:44.576Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101270"
    },
    {
      "nct_id": "NCT01130623",
      "title": "A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma",
        "Neuroblastoma",
        "Wilms Tumor",
        "Osteosarcoma",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Pazopanib (GW786034)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 0,
      "start_date": "2010-05-10",
      "completion_date": "2011-11-18",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-05-22T09:25:44.576Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01130623"
    },
    {
      "nct_id": "NCT02498665",
      "title": "A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes",
        "Glioblastoma Multiforme",
        "Melanoma",
        "Non-Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Sarcoma",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "DSP-7888 Dosing Emulsion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2015-11",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-05-22T09:25:44.576Z",
      "location_count": 8,
      "location_summary": "Denver, Colorado • Atlanta, Georgia • Lafayette, Indiana + 5 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02498665"
    },
    {
      "nct_id": "NCT00365768",
      "title": "Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Neurotoxicity",
        "Peripheral Neuropathy",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Glutamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "5 Years to 21 Years"
      },
      "enrollment_count": 56,
      "start_date": "2004-10",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2016-09-09",
      "last_synced_at": "2026-05-22T09:25:44.576Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00365768"
    },
    {
      "nct_id": "NCT00019630",
      "title": "Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Soft Tissue Sarcoma",
        "Childhood Liver Cancer",
        "Bone Cancer",
        "Brain Tumor",
        "Kidney Tumor"
      ],
      "interventions": [
        {
          "name": "doxorubicin HCl liposome",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-05-22T09:25:44.576Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00019630"
    }
  ]
}